26 results match your criteria Immunotherapeutic Targeting in Children

  • Page 1 of 1

CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors.

Front Oncol 2018 17;8:453. Epub 2018 Oct 17.

Department of Neurosurgery, IU Simon Cancer Center, IU School of Medicine, Indiana University Purdue University Indianapolis, Indianapolis, IN, United States.

T cell chimeric antigen receptor (CAR) technology has allowed for the introduction of a high degree of tumor selectivity into adoptive cell transfer therapies. Evolution of this technology has produced a robust antitumor immunotherapeutic strategy that has resulted in dramatic outcomes in liquid cancers. CAR-expressing T-cells (CARTs) targeting CD19 and CD20 have been successfully used in the treatment of hematologic malignancies, producing sustained tumor regressions in a majority of treated patients. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2018.00453/
Publisher Site
http://dx.doi.org/10.3389/fonc.2018.00453DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199385PMC
October 2018
20 Reads

A Monoclonal Antibody against 6-Acetylmorphine Protects Female Mice Offspring from Adverse Behavioral Effects Induced by Prenatal Heroin Exposure.

J Pharmacol Exp Ther 2019 Jan 25;368(1):106-115. Epub 2018 Oct 25.

Section for Drug Abuse Research, Department of Forensic Sciences, Oslo University Hospital, Oslo, Norway (A.M.S.K., J.M.A., E.L.Ø., S.S., I.L.B.); School of Pharmacy, Faculty of Mathematics and Natural Sciences (A.M.S.K., J.M.A., E.L.Ø.), Institute of Basic Medical Sciences (I.L.B.) and Institute of Clinical Medicine (J.M.), Faculty of Medicine, University of Oslo, Oslo, Norway; and Department of Infectious Disease Immunology (A.A.) and Department of Health Data and Digitalization (J.M.), Norwegian Institute of Public Health, Oslo, Norway

Escalating opioid use among fertile women has increased the number of children being exposed to opioids during fetal life. Furthermore, accumulating evidence links prenatal opioid exposure, including opioid maintenance treatment, to long-term negative effects on cognition and behavior, and presses the need to explore novel treatment strategies for pregnant opioid users. The present study examined the potential of a monoclonal antibody (mAb) targeting heroin's first metabolite, 6-acetylmorphine (6-AM), in providing fetal protection against harmful effects of prenatal heroin exposure in mice. Read More

View Article

Download full-text PDF

Source
http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.118.25
Publisher Site
http://dx.doi.org/10.1124/jpet.118.251504DOI Listing
January 2019
7 Reads

CD8 T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity.

Immunity 2018 Oct 9;49(4):678-694.e5. Epub 2018 Oct 9.

Princess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada; Department of Immunology, University of Toronto, Toronto, ON, M5S 1A8 Canada. Electronic address:

CD8 T cell exhaustion impedes control of chronic viral infection; yet how new T cell responses are mounted during chronic infection is unclear. Unlike T cells primed at the onset of infection that rapidly differentiate into effectors and exhaust, we demonstrate that virus-specific CD8 T cells primed after establishment of chronic LCMV infection preferentially generate memory-like transcription factor TCF1 cells that were transcriptionally and proteomically distinct, less exhausted, and more responsive to immunotherapy. Mechanistically, adaptations of antigen-presenting cells and diminished T cell signaling intensity promoted differentiation of the memory-like subset at the expense of rapid effector cell differentiation, which was now highly dependent on IL-21-mediated CD4 T cell help for its functional generation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10747613183034
Publisher Site
http://dx.doi.org/10.1016/j.immuni.2018.08.002DOI Listing
October 2018
20 Reads

Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma.

Cancer Res 2018 Dec 13;78(23):6621-6631. Epub 2018 Sep 13.

Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.

: Neuroblastoma is the second most common tumor in children. The cause of neuroblastoma is thought to lie in aberrant development of embryonic neural crest cells and is accompanied by low MHC-1 expression and suppression of the NF-κB transcription factor, thereby gearing cells toward escape from immunosurveillance. Here, we assess regulation of the MHC-1 gene in neuroblastoma to enhance its immunogenic potential for therapeutic T-cell targeting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-0545DOI Listing
December 2018
1 Read

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Nat Med 2017 Dec 13;23(12):1416-1423. Epub 2017 Nov 13.

Cancer Institute, University College London, London, UK.

Mature T cell cancers are typically aggressive, treatment resistant and associated with poor prognosis. Clinical application of immunotherapeutic approaches has been limited by a lack of target antigens that discriminate malignant from healthy (normal) T cells. Unlike B cell depletion, pan-T cell aplasia is prohibitively toxic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4444DOI Listing
December 2017
26 Reads

Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.

Pediatr Blood Cancer 2018 Jan 4;65(1). Epub 2017 Sep 4.

Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.

Background: Programmed cell death 1 (PD-1) receptor engagement on T cells by its ligand programmed cell death ligand 1 (PD-L1) is a key mechanism of immune escape, and antibody blockade of the interaction has emerged as an effective immunotherapeutic strategy in some cancers. The role and relevance of the PD-1 checkpoint in Ewing sarcoma (EwS) is not yet understood.

Procedure: Here, we investigated expression of PD-L1 and PD-1 in EwS by immunohistochemistry analysis of pretherapeutic tumor biopsies and in tumor xenografts following treatment with human T cells engineered to express a chimeric antigen receptor (CAR) against the tumor-associated antigen G . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.26719DOI Listing
January 2018
9 Reads

The neoepitope landscape in pediatric cancers.

Genome Med 2017 08 31;9(1):78. Epub 2017 Aug 31.

Department of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee, 38105, USA.

Background: Neoepitopes derived from tumor-specific somatic mutations are promising targets for immunotherapy in childhood cancers. However, the potential for such therapies in targeting these epitopes remains uncertain due to a lack of knowledge of the neoepitope landscape in childhood cancer. Studies to date have focused primarily on missense mutations without exploring gene fusions, which are a major class of oncogenic drivers in pediatric cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-017-0468-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577668PMC
August 2017
26 Reads

New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.

Expert Rev Anticancer Ther 2017 08 5;17(8):725-736. Epub 2017 Jul 5.

a Division of Pediatric Hematology Oncology, Department of Pediatrics , Perlmutter Cancer Center, NYU Langone Medical Center , New York , NY , USA.

Introduction: The improvement in outcomes for children with acute lymphoblastic leukemia (ALL) is one of the greatest success stories of modern oncology however the prognosis for patients who relapse remains dismal. Recent discoveries by high resolution genomic technologies have characterized the biology of relapsed leukemia, most notably pathways leading to the drug resistant phenotype. These observations open the possibility of targeting such pathways to prevent and/or treat relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1347507DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028000PMC
August 2017
9 Reads

Roles of cancer/testis antigens (CTAs) in breast cancer.

Cancer Lett 2017 07 6;399:64-73. Epub 2017 Mar 6.

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University. Nanjing 210004, China. Electronic address:

Breast cancer is the most common cancer diagnosed and is the second leading cause of cancer death among women in the US. For breast cancer, early diagnosis and efficient therapy remains a significant clinical challenge. Therefore, it is necessary to identify novel tumor associated molecules to target for biomarker development and immunotherapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835173014
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2017.02.031DOI Listing
July 2017
7 Reads

The Safety of available immunotherapy for the treatment of glioblastoma.

Expert Opin Drug Saf 2017 Mar 3;16(3):277-287. Epub 2017 Jan 3.

a Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery , Duke University Medical Center , Durham , NC , USA.

Introduction: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Current standard of care involves maximal surgical resection combined with adjuvant chemoradiation. Growing support exists for a role of immunotherapy in treating these tumors with the goal of targeted cytotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2017.1273898DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404815PMC
March 2017
31 Reads

Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Immunotherapy 2016 09;8(9):1097-117

Department of Human Oncology, University of Wisconsin, Madison, WI, USA.

Tumor-specific monoclonal antibodies (mAbs) have demonstrated efficacy in the clinic, becoming an important approach for cancer immunotherapy. Due to its limited expression on normal tissue, the GD2 disialogangloside expressed on neuroblastoma cells is an excellent candidate for mAb therapy. In 2015, dinutuximab (an anti-GD2 mAb) was approved by the US FDA and is currently used in a combination immunotherapeutic regimen for the treatment of children with high-risk neuroblastoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2016-0021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619016PMC
September 2016
3 Reads

Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.

Br J Haematol 2016 05 7;173(4):597-616. Epub 2016 Apr 7.

Department of Pediatrics, New York Medical College, Valhalla, NY, USA.

With the introduction of the anti-CD20 monoclonal antibody rituximab, B-cell non-Hodgkin lymphoma was the first malignancy successfully treated with an immunotherapeutic agent. Since then, numerous advances have expanded the repertoire of immunotherapeutic agents available for the treatment of a variety of malignancies, including many lymphoma subtypes. These include the introduction of monoclonal antibodies targeting a variety of cell surface proteins, including the successful targeting of immunoregulatory checkpoint receptors present on T-cells or tumour cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14078DOI Listing
May 2016
1 Read

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Blood 2015 Jul 3;126(5):629-39. Epub 2015 Jun 3.

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;

Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting the CD19 B cell-associated protein have demonstrated potent activity against relapsed/refractory B-lineage acute lymphoblastic leukemia (B-ALL). Not all patients respond, and CD19-negative relapses have been observed. Overexpression of the thymic stromal lymphopoietin receptor (TSLPR; encoded by CRLF2) occurs in a subset of adults and children with B-ALL and confers a high risk of relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-11-612903DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520878PMC
July 2015
16 Reads

Immunobiology and immunotherapeutic targeting of glioma stem cells.

Adv Exp Med Biol 2015 ;853:139-66

Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd, Los Angeles, CA, 90048, USA.

For decades human brain tumors have confounded our efforts to effectively manage and treat patients. In adults, glioblastoma multiforme is the most common malignant brain tumor with a patient survival of just over 14 months. In children, brain tumors are the leading cause of solid tumor cancer death and gliomas account for one-fifth of all childhood cancers. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2F978-3-319-165
Web Search
http://link.springer.com/10.1007/978-3-319-16537-0_8
Publisher Site
http://dx.doi.org/10.1007/978-3-319-16537-0_8DOI Listing
August 2015
3 Reads

Programmed cell death ligand 1 expression in osteosarcoma.

Cancer Immunol Res 2014 Jul 21;2(7):690-698. Epub 2014 Apr 21.

Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, United States.

Programmed cell death ligand 1 (PDL1, also known as B7H1) is a cell-surface protein that suppresses the cytotoxic CD8(+) T-cell-mediated immune response. PDL1 expression and its clinical relevance in sarcomas are not well understood. Therefore, we sought to measure RNA expression levels for PDL1 in 38 clinically annotated osteosarcoma tumor samples and aimed to determine if PDL1 expression correlates with clinical features and tumor-infiltrating lymphocytes (TIL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-13-0224DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082476PMC
July 2014
14 Reads

B7-H3-mediated tumor immunology: Friend or foe?

Int J Cancer 2014 Jun 30;134(12):2764-71. Epub 2013 Sep 30.

Cancer Research Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.

B7-H3 (CD276), a newly identified member of the B7 family of molecules, is often induced in human tumors and its overexpression is closely correlated with survival, prognosis or tumor grade. Although cancer immunotherapy has not been completely translated into clinical successes, interest has been further enhanced by the realization of these costimulatory molecules' potential as targets to modulate clinical immune responses. Despite ample evidence implicating B7-H3 in tumor immune escape, a steady flow of reports have suggested that it may also have antitumor effects under certain circumstances. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28474DOI Listing

Highlights of the third International Conference on Immunotherapy in Pediatric Oncology.

Pediatr Hematol Oncol 2013 Aug 12;30(5):349-66. Epub 2013 Jun 12.

Department for Stem Cell Transplantation and Immunology, J.W. Goethe-University Hospital, University Hospital for Children and Adolescents, Frankfurt/Main, Germany.

The third International Conference on Immunotherapy in Pediatric Oncology was held in Frankfurt/Main, Germany, October 1-2, 2012. Major topics of the conference included (i) cellular therapies using antigen-specific and gene-modified T cells for targeting leukemia and pediatric solid tumors; (ii) overcoming hurdles and barriers with regard to immunogenicity, immune escape, and the role of tumor microenvironment; (iii) vaccine strategies and antigen presentation; (iv) haploidentical transplantation and innate immunity; (v) the role of immune cells in allogeneic transplantation; and (vi) current antibody/immunoconjugate approaches for the treatment of pediatric malignancies. During the past decade, major advances have been made in improving the efficacy of these modalities and regulatory hurdles have been taken. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08880018.2013.802106DOI Listing
August 2013
10 Reads

Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma.

Oncoimmunology 2013 Jan;2(1):e22620

Department of Paediatric Surgery and Urology; University Children's Hospital; Tuebingen, Germany.

Hepatoblastoma (HB) is the most common liver cancer in children. Recurrence of HB after chemotherapy and surgery is frequent among high-risk patients and is associated with chemoresistance. Immunotherapy may improve poor treatment outcomes in HB patients. Read More

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/onci.22620
Publisher Site
http://dx.doi.org/10.4161/onci.22620DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583930PMC
January 2013
6 Reads

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.

Br J Cancer 2012 Mar 28;106(6):1123-33. Epub 2012 Feb 28.

Department of Pediatric Haematology and Oncology, University Children's Hospital Muenster, Albert-Schweitzer-Campus 1, Muenster, 48149, Germany.

Background: Novel treatment strategies are needed to cure disseminated Ewing sarcoma. Primitive neuroectodermal features and a mesenchymal stem cell origin are both compatible with aberrant expression of the ganglioside antigen G(D2) and led us to explore G(D2) immune targeting in this cancer.

Methods: We investigated G(D2) expression in Ewing sarcoma by immunofluorescence staining. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/bjc201257
Publisher Site
http://dx.doi.org/10.1038/bjc.2012.57DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304425PMC
March 2012
3 Reads

A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.

Am J Respir Cell Mol Biol 2012 Jan;46(1):1-5

Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University, Chicago, Illinois, USA.

Lymphangioleiomyomatosis (LAM) leads to hyperproliferation of abnormal smooth muscle cells in the lungs, associated with diffuse pulmonary parenchymal cyst formation and progressive dyspnea on exertion. The disease targets women of child-bearing age. Complications include pneumothoraces and chylous pleural effusions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1165/rcmb.2011-0215TRDOI Listing
January 2012
2 Reads

Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".

Pediatr Hematol Oncol 2011 Sep;28(6):459-60

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

The Second International Conference on Immunotherapy in Pediatric Oncology was held in Houston, Texas, USA, October 11-12, 2010, to discuss the progress and challenges that have occurred in cutting edge immunotherapeutic strategies currently being developed for pediatric oncology. Major topics included immune targeting of acute lymphoblastic leukemia and pediatric solid tumors, chimeric antigen receptors (CARs) for hematologic malignancies and solid tumors, enhancing graft-versus-leukemia for pediatric cancers, overcoming hurdles of immunotherapy, strategies to active the innate immune system, and moving immunotherapy beyond phase I studies. Significant progress has been made in the last 2 years both in the development of novel immunobiologics such as CARs, and in establishing survival benefits of an anti-GD2 monoclonal antibody in randomized studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08880018.2011.596615DOI Listing
September 2011
1 Read

Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.

J Pediatr Hematol Oncol 2009 Apr;31(4):227-44

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

The first annual conference on immunotherapy in pediatric oncology was held in Bethesda, MD, from September 9 to 10, 2008 to discuss the state-of-the-art of immunotherapeutic strategies currently being explored in pediatric oncology. Major topics included targeting cell surface receptors, understanding and improving T-cell-based therapies, augmenting innate immune strategies, and enhancing graft-versus-leukemia for pediatric malignancies. As can be seen in the summaries of the individual presentations, significant progress has been made in developing preclinical models of pediatric tumors and a variety of novel immunobiologic therapies are approaching, or already in, the clinic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0b013e31819a5d8dDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714285PMC
April 2009
3 Reads

CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.

Adv Drug Deliv Rev 2009 Mar 13;61(3):275-82. Epub 2009 Jan 13.

Children's Research Institute, Children's National Medical Center, Washington, DC 20010-2970, USA.

Neuroblastoma is the most common extracranial solid tumor malignancy of childhood. Although it is generally responsive to treatment, high risk cases of neuroblastoma frequently recur. The prognosis for relapsed cases is extremely poor despite aggressive therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.addr.2008.12.011DOI Listing
March 2009
2 Reads

[Rhabdomyosarcoma lysis by T cells expressing a human autoantibody based chimeric receptor targeting the fetal acetylcholine receptors].

Authors:
S Gattenlöhner

Verh Dtsch Ges Pathol 2006 ;90:264-76

Institut für Pathologie der Universität Würzburg.

Rhabdomyosarcomas (RMSs) are the most frequent malignant soft tissue tumors of childhood. Since even aggressive multimodality treatments including autologous stem cell rescue have failed to improve the < 20 % overall survival rate of children with metastatic RMS, novel treatment approaches are urgently needed. Looking for potential targets for immunotherapies, we identified the gamma subunit of the fetal acetylcholine receptor (fAChR) as a specific and overexpressed membrane antigen in RMS. Read More

View Article

Download full-text PDF

Source
October 2007
1 Read

Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.

Clin Cancer Res 2007 Jun;13(12):3559-67

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Purpose: Among central nervous system malignancies, cytochrome P450 1B1 (CYP1B1) expression has only been characterized in medulloblastoma. An immunotherapeutic agent targeting this antigen was shown to safely stimulate a good immune response. To evaluate the viability of further research efforts targeting this antigen, we examined the expression of CYP1B1 in glial cell malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2430DOI Listing
June 2007
51 Reads
5 Citations
8.722 Impact Factor

The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.

Clin Cancer Res 2004 Jul;10(13):4307-13

Children's Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany.

Purpose: The tumor-associated antigen PRAME, a potential candidate for immunotherapeutic targeting, is frequently expressed in a variety of cancers. However, no information about its presence in neuroblastoma is available to date. We therefore evaluated and quantified PRAME expression in a considerable number of neuroblastoma tumors and assessed its impact on the outcome of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-03-0813DOI Listing
July 2004
3 Reads
  • Page 1 of 1